Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

12:52
11/15/19
11/15
12:52
11/15/19
12:52

Roche to acquire Promedior in up to $1.4B deal

Earlier, Promedior announced that it has entered into a definitive merger agreement for Roche to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Promedior, a privately held clinical-stage biotechnology company based in Lexington, Massachusetts, has successfully advanced PRM-151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier this year for idiopathic pulmonary fibrosis. PRM-151, a recombinant form of human pentraxin-2 protein, has demonstrated both prevention and reversal of fibrosis and opens up new opportunities to treat a wide range of systemic fibrotic diseases. Phase 2 trial results demonstrated that PRM-151 is the first molecule to show significant lung function improvements on top of current therapies in IPF. PRM-151 has also shown promising early clinical trial data in myelofibrosis and its anti-fibrotic mechanism has therapeutic potential in other fibrotic diseases. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390M, plus additional contingent payments of up to $1B based on the achievement of certain predetermined development, regulatory and commercial milestones. The closing of the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

  • 07

    Dec

RHHBY Roche
$0.00

(0.00%)

10/15/19
CANT
10/15/19
NO CHANGE
Target $65
CANT
Neutral
Cantor keeps Neutral on Ionis after Roche boosts Phase 3 study size
Roche (RHHBY) disclosed yesterday that the size of the RG6042 Phase 3 trial in Huntington's increased from 660 people to 801, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. Per company comments, this is driven by high patient demand and potential to increase statistical power, particularly for the Q16W dose, adds the analyst. Merle, however, thinks investors might see this change as suggesting the Phase 3 needed more patients for sufficient powering. For her part, the analyst continues to see Huntington's as a challenging indication to study in a clinical trial setting. The higher patient number should improve the likelihood of statistical success, however, says Merle. The analyst, who believes Huntington's is the key stock focus for Ionis Pharmaceuticals investors, keeps a Neutral rating on Ionis shares with a $65 price target.
11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.

TODAY'S FREE FLY STORIES

IPSEY

Ipsen

$0.00

(0.00%)

05:25
12/09/19
12/09
05:25
12/09/19
05:25
Downgrade
Ipsen rating change  »

Ipsen downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

COIHY

Croda International

$0.00

(0.00%)

05:22
12/09/19
12/09
05:22
12/09/19
05:22
Downgrade
Croda International rating change  »

Croda International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$238.97

-3.9 (-1.61%)

05:18
12/09/19
12/09
05:18
12/09/19
05:18
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$46.05

-0.04 (-0.09%)

, THOR

Synthorx

$24.98

-0.02 (-0.08%)

05:16
12/09/19
12/09
05:16
12/09/19
05:16
Hot Stocks
Sanofi to acquire Synthorx for $68 per share in cash »

Sanofi (SNY) and Synthorx…

SNY

Sanofi

$46.05

-0.04 (-0.09%)

THOR

Synthorx

$24.98

-0.02 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

CHK

Chesapeake

05:15
12/09/19
12/09
05:15
12/09/19
05:15
Recommendations
Chesapeake analyst commentary  »

Chesapeake price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$0.76

0.0421 (5.86%)

05:15
12/09/19
12/09
05:15
12/09/19
05:15
Recommendations
Chesapeake analyst commentary  »

Chesapeake price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRBK

Green Brick

$11.57

0.02 (0.17%)

05:12
12/09/19
12/09
05:12
12/09/19
05:12
Downgrade
Green Brick rating change  »

Green Brick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVR

NVR

$3,777.50

-83.65 (-2.17%)

05:12
12/09/19
12/09
05:12
12/09/19
05:12
Upgrade
NVR rating change  »

NVR upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEGEF

MEG Energy

$0.00

(0.00%)

05:11
12/09/19
12/09
05:11
12/09/19
05:11
Upgrade
MEG Energy rating change  »

MEG Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPC

Marathon Petroleum

$60.17

0.4 (0.67%)

05:10
12/09/19
12/09
05:10
12/09/19
05:10
Downgrade
Marathon Petroleum rating change  »

Marathon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$34.30

0.99 (2.97%)

05:10
12/09/19
12/09
05:10
12/09/19
05:10
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$4.60

0.29 (6.73%)

05:10
12/09/19
12/09
05:10
12/09/19
05:10
Hot Stocks
ObsEva says PRIMROSE 2 Phase 3 trial met primary, secondary efficacy endpoints »

ObsEva reported positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGP

Plains GP Holdings

$17.36

0.24 (1.40%)

05:09
12/09/19
12/09
05:09
12/09/19
05:09
Initiation
Plains GP Holdings initiated  »

Plains GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PAA

Plains All American

$17.30

0.29 (1.70%)

05:08
12/09/19
12/09
05:08
12/09/19
05:08
Initiation
Plains All American initiated  »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

MAKSY

Marks & Spencer

$0.00

(0.00%)

05:06
12/09/19
12/09
05:06
12/09/19
05:06
Upgrade
Marks & Spencer rating change  »

Marks & Spencer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WING

Wingstop

$80.22

0.09 (0.11%)

05:04
12/09/19
12/09
05:04
12/09/19
05:04
Upgrade
Wingstop rating change  »

Wingstop upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

05:00
12/09/19
12/09
05:00
12/09/19
05:00
Downgrade
Macy's downgraded to Sell from Neutral at Goldman Sachs »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORLY

O'Reilly Automotive

$445.56

4.52 (1.02%)

, LOW

Lowe's

$116.25

0.67 (0.58%)

04:57
12/09/19
12/09
04:57
12/09/19
04:57
Downgrade
O'Reilly Automotive, Lowe's, Dick's Sporting, BJ's Wholesale rating change  »

O'Reilly Automotive…

ORLY

O'Reilly Automotive

$445.56

4.52 (1.02%)

LOW

Lowe's

$116.25

0.67 (0.58%)

DKS

Dick's Sporting

$46.21

0.325 (0.71%)

BJ

BJ's Wholesale

$23.54

0.095 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

04:55
12/09/19
12/09
04:55
12/09/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

CHMA

Chiasma

$5.27

-0.04 (-0.75%)

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call »

Biotechnology Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OPRX

OptimizeRx

$9.09

0.29 (3.30%)

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
OptimizeRx management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

SHOO

Steven Madden

$42.85

0.55 (1.30%)

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
Steven Madden management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ARQL

ArQule

$9.67

0.15 (1.58%)

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
ArQule to hold an investor conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
JPMorgan integrated oils analyst to hold an analyst/industry conference call »

Integrated Oils &…

ARQL

ArQule

$9.67

0.15 (1.58%)

04:55
12/09/19
12/09
04:55
12/09/19
04:55
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.